Discussion {#s2}
==========

Icotinib is a selective, oral tyrosine kinase inhibitor (TKI) targeting EGFR \[[@B1]\]. Its clinical investigation began in 2007, which included dose escalation and assessment of different dosing schedules \[[@B2]--[@B4]\]. MTD was not reached in these studies, and the recommended dose was established at 125 mg \[[@B2]--[@B6]\]. Oral icotinib was rapidly absorbed and eliminated in NSCLC patients, with a T~max~ of 3 hours and a t~1/2~ of 6 hours \[[@B4], [@B7]\]. Increased drug absorption and exposure were observed when icotinib was administered with high-fat and high-calorie food \[[@B4]\]. Additionally, Ni et al. reported a significant relationship between drug exposure and clinical benefits \[[@B7]\], whereas Zhao et al. found no dose, exposure, safety/efficacy association in another study \[[@B3]\].

The present study documented a relatively higher incidence of AEs in patients receiving higher-dose (250--625 mg) icotinib, with an MTD of 500 mg three times per day The dose-limiting toxicities (DLTs) included grade 3 rash and grade 3 hand and foot syndrome ([Table 1](#T1){ref-type="table"}). Three patients had serious AEs (SAEs; 1 in the 500-mg group and 2 in the 625-mg group); all SAEs were ameliorated by discontinuation or dose reduction. Oral icotinib is rapidly absorbed and eliminated, which was consistent with the results obtained from previous studies assessing low-dose icotinib \[[@B2], [@B4], [@B7]\]. Dose-dependent increases in icotinib C~max~ and area under the curve (AUC) were observed over the dose ranges of 250--350 mg and 400--625 mg, which may be due to its solubility in water ([Fig. 1](#F1){ref-type="fig"}). This trend was also seen in a population pharmacokinetic study, in which icotinib displayed a saturated absorption rate of 204 (oral icotinib, 350 mg) and 245 (oral icotinib, 600 mg) μg per hour in healthy persons \[[@B9]\]. No dose, exposure, safety/efficacy relationship was found in our study.

Antitumor activity was observed over the entire dose range (250--625 mg). The overall response rate (ORR) and disease control rate (DCR) were 23.1% and 53.9%, respectively. In another phase I study evaluating icotinib, tumor response was shown from 100 to 150 mg with an ORR of 21.9% and DCR of 43.8% \[[@B2]\]. These results suggested that the safe and effective range for icotinib is 100--500 mg.

In summary, good tolerability, feasibility of prolonged treatment, antitumor activity, and pharmacological profile of higher-dose icotinib were shown in the present study, which support the application and further investigation of higher-dose icotinib.

Trial Information {#s3}
=================

DiseaseLung Cancer: NSCLCStage of disease / treatmentMetastatic / AdvancedPrior Therapy1 prior regimenType of study - 1Phase IType of study - 23+3 designPrimary EndpointToxicityPrimary EndpointTolerabilitySecondary EndpointMaximum Tolerated DoseSecondary EndpointPharmacokineticsSecondary EndpointEfficacyAdditional Details of Endpoints or Study DesignThis study was conducted between October 9, 2009, and June 15, 2011. Patients were assigned sequentially to escalating dose levels of icotinib following a 3+3 design with a starting dose of 250 mg three times per day. Within a 28-day cycle, a single dose of icotinib was administered orally on day 1 and day 7, followed by 24-hour blood sampling for pharmacokinetics (PK) assessments. For the remaining days, icotinib was administered three times daily. After the first cycle, all patients received continuous icotinib until disease progression or unacceptable toxicities. The doses to be investigated were 300 mg, 350 mg, 400 mg, 500 mg and 625 mg; at least 3 patients were treated in each cohort.DLTs were defined as any grade 3 or higher toxicity per Common Terminology Criteria for Adverse Events, version 3.0. The MTD was the lower dose after the one at which 1 of 3 or 2 of 6 patients developed a DLT. The decisions for dose escalation were based on the observed toxicities during the first treatment cycle (28 days). Dose escalation was designed to be stopped when MTD or 625 mg was achieved.In case of DLT, icotinib could be discontinued for no more than 14 days. If DLT was not relieved after discontinuation, icotinib could be reduced no more than twice by one dose level in the same patient. *EGFR* mutation status was not a requirement in this study.Investigator's AnalysisActive and should be pursued further

Drug Information {#s4}
================

Drug 1Generic/Working nameIcotinibTrade nameConmanaCompany nameBetta Pharmaceuticals Co., Ltd.Drug typeSmall moleculeDrug classEGFRDosemg per flat doseRoutep.o.Schedule of AdministrationOrally administered three times daily

Patient Characteristics {#s5}
=======================

Number of patients, male14Number of patients, female12StageTNM StagingIIIB: 5IV: 21AgeMedian (range): 57 (34, 70)Number of prior systemic therapiesMedian (range): 2 (1, 11)Performance Status: ECOG0 --- 71 --- 192 ---3 ---Unknown ---OtherPrior treatment Chemotherapy: 26No. of previous chemotherapy 1: 22 ≥2: 4 Radiotherapy: 5 Surgery: 5Cancer types or histologic subtypesAdenocarcinoma, 22Squamous cell carcinoma, 1Not clear, 3

Primary Assessment Method {#s6}
=========================

**Control Arm: Total Patient Population**Number of patients enrolled26Number of patients evaluable for toxicity26Number of patients evaluated for efficacy26Response assessment CR*n* = 0 (0)Response assessment PR*n* = 6 (23.1)Response assessment SD*n* = 8 (30.8)Response assessment PD*n* = 12 (46.1)(Median) duration assessments PFS59 days, confidence interval (CI): 33--227(Median) duration assessments OS308 days, CI: 262--516(Median) duration assessments response duration227 days

Adverse Events {#s7}
==============

Serious Adverse Events {#s8}
======================

Pharmacokinetics/Pharmacodynamics {#s9}
=================================

Assessment, Analysis, and Discussion {#s10}
====================================

CompletionStudy completedInvestigator's AssessmentActive and should be pursued further

This phase I study demonstrated that oral icotinib was well tolerated at the dose range of 250--500 mg in pretreated, advanced NSCLC patients. The MTD was established at 500 mg. Incidence of AEs was higher than seen in prior studies evaluating normal dose (125 mg three times daily) without a new safety signal \[[@B1], [@B2]\]. In addition, favorable antitumor activities and PK profile was also documented.

Phase I studies of icotinib began in 2007 and consisted of dose-escalation and assessment of different dosing schedules in both healthy persons and patients with solid tumors \[[@B3]--[@B5]\]. Icotinib was well tolerated in healthy persons with a single dose ranging from 75 to 1,025 mg, even at the highest dose \[[@B5]\]. In NSCLC patients, mild and manageable AEs were seen when icotinib was orally administered at a dose of 75--150 mg three times daily \[[@B3]\]. The most frequently occurring AEs were rash (16 of 36 \[44.4%\]) and diarrhea (8 of 36 \[22.2%\]); the only 2 grade 3 AEs (grade 3 hepatic aminotransferase elevation and grade 3 mouth ulceration) were recorded in the 500- and 625-mg group, with no other grade 3 or higher AEs. MTD was not reached, and the recommended dose was established at 125 mg \[[@B3]\]. Another phase I study assessed the safety and activity of icotinib in 40 NSCLC patients with different dosing schedules (150 and 200 mg twice daily and 125 mg three times daily) \[[@B4]\]. The safety profile was similar to that in other studies, with an overall incidence of 65%. However, an interstitial lung disease (ILD) was recorded in the 200-mg twice-daily group \[[@B4]\].

Oral icotinib was rapidly absorbed and eliminated in healthy persons with a T~max~ of 2 hours and a t~1/2~ of 6 hours \[[@B5]\]. Increased drug absorption and exposure of icotinib were observed when the drug was administered with high-fat and high-calorie food \[[@B5]\]. Similar PK patterns of icotinib were documented in cancer patients. A 3-hour T~max~ and a 6-hour t~1/2~ were seen after oral icotinib at 75--150 mg three times daily \[[@B3]\]. Steady state was reached within 15 days. Similar values for T~max~ and t~1/2~ were demonstrated in a study performed in NSCLC patients with icotinib at 150 and 200 mg twice daily \[[@B6]\]. Both studies revealed increased drug exposure with rising dose. Additionally, Ni et al. reported a significant relationship between drug exposure and clinical benefits \[[@B7]\], whereas Zhao et al. found no dose, exposure, safety/efficacy association in another study \[[@B3]\].

The present study documented a relatively higher incidence of AEs in patients receiving higher-dose (250--625 mg) icotinib, with an MTD of 500 mg three times per day. Most toxicities were mild to moderate, and only 2 grade 3 rash and 1 grade 3 hand and foot syndrome were recorded ([Table 1](#T1){ref-type="table"}). The most frequent AEs were grade 1 and 2 rashes (14 of 26 \[53.8%\]), diarrhea (6 of 26 \[23.1%\]), and mouth ulceration (3 of 26 \[11.5%\]). Three patients had SAEs (1 in the 500-mg group and 2 in the 625-mg group), and all SAEs were relieved after discontinuation or dose reduction. No changes in icotinib safety profile were observed during prolonged administration. PK analysis indicated that single-dose oral icotinib is rapidly absorbed and eliminated, which was consistent with the results obtained from previous studies assessing low-dose icotinib \[[@B3], [@B5], [@B6]\]. Dose-dependent increases in icotinib C~max~ and AUC were observed over the dose ranges of 250--350 mg and 400--625 mg, which may be due to the drug's solubility in water ([Fig. 1](#F1){ref-type="fig"}). This trend was also seen in a population PK study, in which icotinib displayed a saturated absorption rate of 204 (icotinib 350 mg), and 245 (icotinib 600 mg) μg per hour in healthy persons \[[@B8]\]. In addition, no dose, exposure, safety/efficacy relationship was found in our study.

ILD is a major safety concern for EGFR TKIs, with an morbidity and mortality of 1.6% and 13.0%, respectively \[[@B9]\]. For icotinib, 1 and 4 drug-induced ILDs were reported in a phase I study (*n* = 40) and a postmarketing phase IV study that included 6,087 patients, respectively \[[@B2], [@B4]\]; no ILDs were observed in the current study.

Clinical activities of icotinib were revealed in patients with heavily pretreated NSCLC, and evidence of antitumor activity was observed over the entire dose range (250--625 mg). The ORR and DCR were 23.1% and 53.9%, respectively. In another phase I study evaluating icotinib from 75 to 150 mg, tumor responses were observed from 100 to 150 mg with an ORR of 21.9% and DCR of 43.8% \[[@B3]\]. These results suggested that the safe and effective dose range for icotinib is 100--500 mg. Icotinib also provided clinical benefit in terms of progression-free survival (PFS; 59 days) and overall survival (308 days), and PFS for patients with disease control was 227 days.

Information available on the efficacy and safety of higher-dose icotinib has increased with time. Liu et al. reported that patients who progressed with 125-mg icotinib continued to benefit from higher-dose icotinib (250 or 375 mg), with tolerable toxicities \[[@B10]\]. Higher-dose icotinib also had potential activity in treating brain metastasis (BM). A phase I dose-escalation study evaluated the safety of the combination of icotinib and whole-brain radiotherapy from BM in patients with NSCLC bearing *EGFR* mutations \[[@B11]\]. The MTD of icotinib was 500 mg, and icotinib penetration into brain achieved the peak at a dose of 375 mg by cerebrospinal fluid analysis. Tumor response was seen in 12 of 15 patients; the remaining 3 patients achieved stable disease as best response \[[@B11]\]. Higher-dose icotinib was also explored in other solid tumors; Huang et al. found icotinib was effective and well-tolerated in esophageal cancer with an ORR of 16.7%, and a DCR of 48.9% \[[@B12]\]. Currently, icotinib has been approved by the China Food and Drug Administration for the treatment of pretreated, unselected NSCLC (July 2011) and NSCLC positive for *EGFR* mutation (November 2014).

Our study has limitations, especially the lack of biomarker analysis. In addition, *EGFR* mutation testing was not widely recognized for previously treated patients in China during the study design. Furthermore, these results should be considered in the context that this study was a single-arm trial with limited sample size.

In summary, good tolerability, feasibility of prolonged treatment, antitumor activity, and an acceptable pharmacological profile of higher-dose icotinib were shown in the present study. The MTD was established at 500 mg three times daily, and the safe and effective dose ranged from 250 to 500 mg, which supports the application and further investigation of higher-dose icotinib.
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![Mean plasma concentration-time profiles of icotinib. **(A)**: On day 1 after single oral doses of 250, 300, 350, 400, 500, and 625 mg. The error bars represent SDs. **(B)**: On day 7 after multiple oral doses of 250, 300, 350, 400, 500, and 625 mg. The error bars represent SDs.](theoncologist_16256CTR_f1){#F1}
